Abstract
Gastrointestinal Neuroendocrine Tumors (GI-NET) are one of the rarest cancers that occur with an annual global incidence of 2.5-5/100000 patients. Gastrointestinal NeT is the second cancer that affects any individuals, after cancer of the colorectal region. Early identification and early intervention will prevent the mortality of individuals dying due to gastrointestinal neuroendocrine tumors. The main element of prevention is early identification; hence clinicians can identify the rarest cases and can receive enlighten insights to reduce the mortality due to the rarest diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
